Clinical Considerations of Clostridia Bacterial Concerns:Part 2

July 15, 2021

https://biocidin.wistia.com/medias/vgvnolnqhj

Clinical Considerations of Clostridia Bacterial Concerns:  Part 2

Dr. Kurt Woeller opened our eyes to the breadth of symptoms that can manifest with Clostridium difficile and other pathogenic species in Part 1. So what’s the best way to confirm your suspicions that C. diff is involved?

In Part 2 Dr. Woeller identifies the methods he finds most effective for detecting C. diff in patients, including both conventionally accepted as well as alternative techniques:

  • Toxin detection via stool testing
  • Organic acids test
  • Stool analysis and culture

Learn from Dr. Woeller’s extensive experience as he discusses his expert recommendations on optimal laboratory testing methods.

You can watch the video in the link or read the article.

For more:  

Category:

C-diff, Uncategorized

Comments Off on Clinical Considerations of Clostridia Bacterial Concerns:Part 2

Tick Academy

Tick Academy – Announcement Flyer

Tick Academy

cropped-ipm_tickproblem_banner_05

September 13-15, 2021, 10:00a.m. – 2:00pm

Please join the Tick IPM Working Group for the second annual Tick Academy! The Tick Academy is the premier event for researchers, educators, students, public health professionals, pest control professionals, public-space managers and citizen scientists interested in learning more about what they can do to stop the spread of ticks and tickborne diseases in their communities. This virtual event will feature twelve presentations over three, four-hour sessions where presenters will share the newest information from the field. Participants will be able to ask questions of these world-class tick experts.

Topics covered:

  • Tick management Tickborne disease prevention
  • Recent discoveries of emerging pathogens
  • Public perceptions of risk Diversity and identification of ticks
  • Vaccine developments

Instructors:

  • Alejandro Calixto, PhD, Director, New York State Integrated Pest Management Program
  • Bieneke Bron, PhD, DVM, Scientist, Wageningen University & Research
  • Bob Maurais, President, Mainely Ticks, Inc.
  • Bobbi Pritt, MD, MSc, FCAP, DTMH, Director, Clinical Parasitology Laboratory, Mayo Clinic
  • Jean Tsao, PhD, Associate Professor, Michigan State University
  • Jordan Mandli, PhD, MPH, Research Associate, University of Wisconsin-Madison
  • Kirby Stafford, PhD, Chief Scientist, State Entomologist, The Connecticut Agricultural Experiment Station
  • Lorenza Beati, MD, PhD, Curator U.S. National Tick Collection, Georgia Southern University
  • Susan Paskewitz, PhD, Professor & Co-Director, Midwest Center of Excellence for Vector-Borne Disease
  • Tammi Johnson, PhD, Assistant Professor of Wildlife Disease Ecology, Texas A&M University
  • Tom Mather, PhD, Professor & Director, University of Rhode Island Center for Vector-Borne Diseases
  • Xia Lee, PhD, Postdoctoral Researcher, Midwest Center of Excellence for Vector-Borne Disease

Register in top link

Category:

Activism, Prevention, Ticks, vaccines

Comments Off on Tick Academy

Sharyl Attkisson: Big Tech Is Censoring Key Facts About COVID Vaccine Safety

July 14, 2021

https://childrenshealthdefense.org/defender/sharyl-attkisson-big-tech-censoring-facts-covid-vaccine-safety/

Sharyl Attkisson: Big Tech Is Censoring Key Facts About COVID Vaccine Safety

Investigative journalist Sharyl Attkisson said on “The Sharyl Attkisson Podcast” that Big Tech “is censoring factual and truthful information while propagating false information” about the safety of COVID vaccines.
No matter how diligent your research, finding truthful information about the risks of COVID vaccines can be tricky.

No matter how diligent your research, finding truthful information about the risks of COVID vaccines can be tricky, according to investigative journalist Sharyl Attkisson.

During a recent segment of “The Sharyl Attkisson Podcast,” Attkisson said information about the safety of COVID vaccines and other medicines is often “falsely portrayed by propagandists and pharmaceutical interests.”

COVID vaccines are being used on an “emergency basis,” said Attkisson, meaning they weren’t subjected to the same safety trials vaccines normally go through before hitting the market. “That’s why we’re learning things in real time as we go,” she said.

Attkisson said the fact that some scientists are calling for an immediate halt to the use of COVID vaccines, at least until new safety measures are put in place, is evidence of mounting concerns about the safety of the vaccines.

Attkisson cited a paper by 57 scientists from 17 countries warning of the potential risks of vaccinating the world with shots that lack adequate safety testing. The authors of the paper, published in Authorea, demanded answers from international health agencies, regulatory authorities, governments and vaccine developers.

The authors wrote:

“Since the start of the COVID-19 outbreak, the race for testing new platforms designed to confer immunity against SARS-CoV-2, has been rampant and unprecedented, leading to conditional emergency authorization of various vaccines. Despite progress on early multidrug therapy for COVID-19 patients, the current mandate is to immunize the world population as quickly as possible. The lack of thorough testing in animals prior to clinical trials, and authorization based on safety data generated during trials that lasted less than 3.5 months, raise questions regarding vaccine safety.

“Given the high rate of occurrence of adverse effects that have been reported to date, as well as the potential for vaccine-driven disease enhancement, Th2-immunopathology, autoimmunity and immune evasion, there is a need for a better understanding of the benefits and risks of mass vaccination, particularly in groups excluded from clinical trials.”

Listen here:  https://sharylattkisson.com/2021/07/hard-facts-on-covid-19-vaccine-safety-and-conflicting-advice-podcast/

© [7/12/21] Children’s Health Defense, Inc. This work is reproduced and distributed with the permission of Children’s Health Defense, Inc. Want to learn more from Children’s Health Defense? Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. Your donation will help to support us in our efforts.

_____________________

**UPDATE July 15, 2021**

In an unprecedented totalitarian move, an advisory put out by the U.S. Surgeon General is recommending that Big Tech companies (Facebook, Twitter, Youtube, etc) impose consequences for accounts that violate the private companies’ own policies.  In other words the government is telling privately owned companies what to do – particularly with regard to what they call ‘misinformation’, defined as ‘information that is false, inaccurate, or misleading according to the best available evidence.’

This article states Facebook now says medical studies published in peer-reviewed journals are FAKE NEWS if they conclude things it disagrees with.  One paper in question was published in JAMA, revealing that masking schoolchildren exposes them to dangerously high intake of carbon dioxide.  This paper was recently retracted, by JAMA but a German study on nearly 26,000 children found the exact same thing, not to mention numerous studies have shown them to be pathogen reservoirs. These are unacceptable findings to Zuckerberg and go against what Fauci said at one point before flip-flopping a few times, therefore must be eliminated from planet earth.  A year ago, I posted a PPE developer’s experience with having trouble breathing using the N95 mask and his subsequent experiment showing the lowered oxygen levels, but experience and expert testimony don’t matter anymore.  He believes lack of oxygen isn’t as noticeable with other masks due to the gaps and holes – but that these very gaps and holes make them ineffective against a virus; however, wearing masks continuously for hours every day has never been done or studied, therefore the long-term impact has been unknown until now.

When users or pages attempt to share either of the two articles, a warning pops up from Facebook’s “fact checkers” explaining that the peer-reviewed science is a “hoax”.  I’m certain FB also would not approve of sharing the fact that graphene oxide has been found in masks.

In case you missed it, Big Tech has already been censoring and shutting down accounts that disagree with what the government is peddling, which includes theirown infective treatments and injections they erroneously call “vaccines.”

Our own government is guilty of ‘misinformation’ but has gotten away with it because they hold the power. They have lied about COVID being isolated, the effectiveness of masks, testing, actual case counts of COVID, that there are cheap, effective treatments, the true cause of death, and on the effectiveness and safety of the COVID injection, which they own half the patent on.

While the U.S. General states that, “health misinformation is an urgent threat to public health. It can cause confusion, sow mistrust, and undermine public health efforts, including our ongoing work to end the COVID-19 pandemic,” they are the ones repeatedly sowing misinformation and by keeping life-saving treatment from sick people so they can push their own lucrative treatments and injections.

Interestingly, they call those sowing ‘misinformation’ ‘super-spreaders.”  This is not by accident.  Bullies have always used name-calling in their arsenal of tools.

Power corrupts; absolute power corrupts absolutely.

There is a information war going on.  Make sure you are equipping yourself with facts that haven’t been twisted by those with vested interests.

For more:

Category:

Activism, vaccines, Viruses

Comments Off on Sharyl Attkisson: Big Tech Is Censoring Key Facts About COVID Vaccine Safety

Clinical Considerations of Clostridia Bacterial Concerns – Part 1

Clostridium difficile is labeled as one of the organisms of greatest concern for antibiotic resistance by the National Institutes of Health. 

Most healthcare practitioners associate it with acute colitis and diarrhea. However, it can also colonize the gastrointestinal tract, creating chronic symptoms that are harder to recognize.

Colonization of a number of problematic Clostridia species (and the metabolites they produce) can create neurological irritation and neurotransmitter imbalances, and has been implicated in:

  • Attention issues
  • Mood disorders
  • Neurological conditions

In this three-part series, Dr. Kurt Woeller delivers clinically relevant information that comes from years of working with neurologically symptomatic patients, his experience in specialized testing, and from a place of commitment to excellent patient care.

Dive into Part 1 where Dr. Woeller introduces the breadth of alternative symptoms that can manifest with Clostridium difficile (C. diff) and other pathogenic species.Stay tuned for upcoming Parts 2 and 3 where Dr. Woeller identifies methods most effective for detecting C. diff and discusses his most trusted therapeutics for addressing positive test results.Best for your health,
image

Kurt N. Woeller, DO, has been a functional and integrative medicine physician and a biomedical autism treatment specialist for over two decades. A respected author, international lecturer, and educator, he provides healthcare practitioner education through his online Integrative Medicine Academy.

Dr. Woeller serves as a clinical consultant and educator for both BioHealth Laboratory and Great Plains Laboratory (GPL). At GPL, he teaches the Organic Acid Test (OAT) interpretation and implementation course.

At his private practice in Bend, OR, he focuses on specialized diagnostic testing and treatment for individuals with complex medical conditions like autism, autoimmune and neurological disorders.

_____________________

For more:

 
  •  

Category:

Candida, Treatment

Comments Off on Clinical Considerations of Clostridia Bacterial Concerns – Part 1

FDA Accepts Investigational Drug for Lyme Prevention

https://www.globenewswire.com/en/news-release/2021/05/04/2222816/0/en/Tarsus-Pharmaceuticals-Inc-Announces-FDA-Acceptance-of-Investigational-New-Drug-Application-for-TP-05-for-Lyme-Disease-Prevention

Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention

 | Source: Tarsus Pharmaceuticals, Inc

Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention

Allows initiation of Phase 1 study to evaluate safety, pharmacokinetics, and dosing

More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms

IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease. With this IND acceptance, Tarsus will initiate a Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of TP-05 in healthy volunteers. Study initiation is anticipated in July.

“We are pleased that the FDA has accepted the IND for TP-05, which is an important milestone in our pipeline development. Currently, there are no approved pharmacological prophylactic options for tick kill and preventing transmission of Lyme disease, which has the potential to cause severe, often debilitating symptoms with permanent and irreversible damage,” said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus. “There is a significant unmet need for a therapeutic to quickly and reliably prevent this disease that can lead to poor outcomes for so many people. We look forward to initiating our clinical development program for TP-05 and advancing the path for this much-needed therapeutic for Lyme disease prevention.”

Lyme disease is transmitted to humans after the bite of a blacklegged tick infected with the Borrelia bacteria. It is the most common vector-borne disease in the United States and can result in inflammation, nerve, joint and muscle pain and swelling, numbness, shortness of breath and – in severe cases – neurological complications such as facial palsy, vision issues, and meningitis symptoms, including severe headaches and neck stiffness. Lyme disease impacts more than 300,000 people in the U.S. each year and over 30 million are at high or moderate risk for contracting the disease.

TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills ticks by blocking the parasite-specific GABA-CI channels. TP-05 is believed to be the only non-vaccine based therapeutic in development and is designed to rapidly provide systemic blood levels of lotilaner, and kill infected ticks attached to the human body before they can transmit the Borrelia bacteria that causes Lyme disease. In addition to the prevention of Lyme disease, Tarsus is also exploring TP-05 for the community prevention of malaria.

Tarsus is currently conducting a pivotal trial evaluating the efficacy and safety of TP-03, a topical ophthalmic formulation of lotilaner, for the treatment of Demodex blepharitis, a common ocular condition caused by an infestation of Demodex mites.

About TP-05
TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills parasites by inhibiting parasite-specific GABA-Cl channels. Tarsus is studying TP-05 for the prevention of Lyme disease. In July of 2021, Tarsus will initiate a Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) study to evaluate the safety, tolerability and pharmacokinetics (PK) of TP-05 in healthy volunteers. In addition to Lyme disease, Tarsus is also exploring TP-05 for the community prevention of malaria.

About Lyme Disease
Lyme disease is the most common vector-borne disease in the United States, transmitted to humans after the bite of a blacklegged tick infected by the bacterium Borrelia burgdorferi. Over 30 million Americans are at high or moderate risk of contracting Lyme disease and there are approximately 300,000 – 400,000 cases in the U.S. each year. People who spend extended amounts of time outdoors in wooded, grassy areas are at higher risk of getting the infection. Data from the Centers for Disease Control (CDC) shows that the risk of Lyme disease is spreading to new geographical areas, resulting in a significant need for prophylactic solutions. Currently, there are no FDA-approved pharmacological prophylactic options for Lyme disease.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in a pivotal Phase 2b/3 trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease.

Media Contact:
SuJin Oh
Shop PR
(917) 841-5213
sujin@shop-pr.com

Investor Contact:
Patti Bank
Westwicke Partners, an ICR company
(415) 513-1284
IR@tarsusrx.com

___________________

For more on Lotilaner:

  • https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-017-2471-3
  • https://vetmed.illinois.edu/pet_column/fda-alert-on-flea-medications/  Only medications in the isoxazoline class of flea and tick medications are under investigation at this time. This includes Bravecto, Nexgard, Credelio, and Simparica (brand names for fluralaner, afoxolaner, lotilaner, and sarolaner).
  • Credelio contains the ingredient, lotilaner, which is an antiparasitic drug that kills the fleas and ticks that live on your pet’s body surface. Lotilaner blocks the transfer of chloride ions from passing through cell membranes, which causes uncontrolled neuromuscular activity and results in the death of fleas and ticks. Credelio starts killing fleas within 4 hours of administration and kills over 99% of fleas within 8 hours of administration. Credelio starts killing ticks* in 4 hours and 98.7% killed within 8 hours. *(Ixodes ricinus)  Source
  • https://ivcjournal.com/isoxazoline-flea-and-tick/  On September 20, 2018, the U.S. Food and Drug Administration (FDA) warned animal caregivers and veterinarians about the risk of serious neurologic events, including seizures, muscle tremors and ataxia, in dogs and cats treated with certain flea and tick medications. The warning applies to medications in the isoxazoline class — specifically, NexGard (afoxalaner), Bravecto (fluralaner), Simparica (sarolaner) and Credelio (lotilaner). The FDA updated their release on April 22, 2019 to include another recently-approved product in the isoxazoline class — namely, Revolution Plus (selamectin and sarolaner topical solution). The isoxazoline class encompasses a group of azolyl phenyl chemical compounds originally developed as parasiticides about 20 years ago. They are now widely used around the world. Adverse reactions to these compounds appear to affect animals randomly, although those with certain chronic diseases, the young and elderly, and animals that are immune-compromised or have the genetic mutation of the MDR1 gene are at higher risk.

Category:

Lyme, Prevention, Treatment

Comments Off on FDA Accepts Investigational Drug for Lyme Prevention